Patients Specialty medication access hinges on a 48-hour window The vast majority of healthcare providers (HCPs) say that PA-related delays directly harm patient outcomes.
Patients More than a discount: How intelligent copay programmes are r... Brian Laird explains a more dynamic, data-driven approach to copay is redefining affordability, creating a new standard for balancing patient support.
Sales & Marketing Why commercialisation is the next frontier for digital innov... In March, Cigna and its pharmacy benefit manager subsidiary Evernorth announced plans to limit spending increases on GLP-1 drugs at 15% per year.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.